```html

X‑linked Primary Immunodeficiency (Wiskott‑Aldrich Syndrome)

Overview

Wiskott‑Aldrich Syndrome (WAS) is a rare, X‑linked primary immunodeficiency disorder caused by mutations in the WAS gene. The gene encodes the Wiskott‑Aldrich Syndrome protein (WASP), which is crucial for the development and function of blood cells, especially T‑cells, B‑cells, platelets, and dendritic cells. Defective WASP leads to three hallmark problems:

• Immune dysfunction – increased susceptibility to bacterial, viral, and fungal infections.
• Thrombocytopenia – low platelet count with abnormally small platelets, causing bleeding tendency.
• Eczema – often severe and chronic.

Because the gene is located on the X chromosome, virtually all affected individuals are biological males. Female carriers usually have no symptoms, though rare lyonization (X‑inactivation) can cause mild manifestations.

Prevalence: Approximately 1–4 per 1 million live births worldwide (Mayo Clinic, 2023). The disorder is slightly more common in populations with higher rates of consanguinity.

Symptoms

Symptoms typically appear in infancy or early childhood, but the severity can vary widely, ranging from classic WAS to milder “X‑linked thrombocytopenia” (XLT). Below is a complete symptom list with brief descriptions.

Immune‑related manifestations

• Recurrent infections: Otitis media, sinusitis, pneumonia, skin abscesses, and gastrointestinal infections. Pathogens often include Staphylococcus aureus, Streptococcus pneumoniae, and CMV.
• Pneumocystis jirovecii pneumonia (PCP): A hallmark opportunistic infection in untreated patients.
• Viral infections: Persistent or severe varicella‑zoster, herpes simplex, and respiratory syncytial virus.
• Fungal infections: Candida or Aspergillus species, especially in those receiving immunosuppressive therapy.

Hematologic / bleeding manifestations

• Thrombocytopenia: Platelet counts often < 50 × 10⁹/L; platelets are small (low mean platelet volume).
• Bruising, petechiae, and purpura: Spontaneous or after minimal trauma.
• Epistaxis and gingival bleeding.
• Intracranial hemorrhage: Rare but life‑threatening, particularly in infants with severe thrombocytopenia.

Dermatologic features

• Eczema: Often severe, chronic, and may be misdiagnosed as atopic dermatitis.
• Skin infections: Secondary bacterial infection of eczematous lesions.

Autoimmune and inflammatory conditions

• Autoimmune hemolytic anemia (AIHA).
• Immune thrombocytopenic purpura (ITP).
• Rheumatologic disease: Arthritis, vasculitis, or inflammatory bowel disease‑like colitis.

Malignancy risk

• Wiskott‑Aldrich–type lymphoma: Usually diffuse large B‑cell lymphoma, often presenting in adolescence or early adulthood.
• Acute myeloid leukemia (AML).

Other possible findings

• Growth retardation.
• Developmental delay (more common in severe forms).
• Recurrent oral ulcers.

Causes and Risk Factors

The disease is caused by loss‑of‑function mutations in the WAS gene (Xq11.22‑q13). Over 300 distinct mutations have been reported, including missense, nonsense, splice‑site, and small deletions.

Genetic inheritance

• X‑linked recessive: A mother who carries a pathogenic variant has a 50 % chance of passing the mutant allele to each son (who will be affected) and a 50 % chance of passing it to each daughter (who becomes a carrier).
• De novo mutations: Approximately 30 % of cases arise spontaneously, with no family history.

Risk factors for a severe phenotype

• Null mutations (complete loss of WASP) → classic WAS with severe immunodeficiency.
• Late diagnosis (≥2 years of age) often correlates with higher rates of autoimmune disease and malignancy.
• Family history of early‑onset severe infections or unexplained bleeding.

Diagnosis

Early recognition is essential for improving outcomes. Diagnosis combines clinical suspicion with laboratory and genetic testing.

Initial laboratory evaluation

• Complete blood count (CBC) with peripheral smear: Low platelet count; small platelets on smear.
• Immunoglobulin levels: Typically low IgM, normal or elevated IgA/IgE, and variable IgG.
• Lymphocyte phenotyping (flow cytometry): Reduced CD8⁺ T‑cells, abnormal CD19⁺ B‑cell numbers, and diminished NK cell activity.
• Functional assays: T‑cell proliferation in response to mitogens (often impaired).

Definitive testing

• WASP protein expression: Intracellular flow cytometry using a WASP‑specific antibody. Absent or markedly reduced signal supports diagnosis.
• Molecular genetic testing: Targeted next‑generation sequencing (NGS) panel for primary immunodeficiencies or whole exome sequencing can identify the specific WAS mutation. Sanger confirmation is standard practice.

Additional studies

• Bone marrow aspirate/biopsy (if malignancy suspected).
• Imaging (CT or MRI) for chronic lung disease or lymphoma staging.

Diagnostic criteria (CDC/NIH)

Diagnosis is confirmed when a pathogenic WAS mutation is identified **and** at least one of the following is present:

1. Thrombocytopenia with small platelets
2. Eczema or severe dermatitis
3. Recurrent bacterial/viral infections

Treatment Options

Treatment aims to prevent infections, control autoimmunity, manage bleeding, and ultimately correct the underlying genetic defect.

Hematopoietic stem cell transplantation (HSCT)

• Curative therapy: Matched sibling donor or matched unrelated donor transplantation offers the best long‑term survival (70–80 % event‑free survival in recent series).
• Reduced‑intensity conditioning regimens have lowered transplant‑related mortality, especially in infants.
• Pre‑transplant considerations: control active infections, ensure adequate organ function, and perform donor‑specific antibody screening.

Gene therapy (experimental)

• Autologous CD34⁺ stem cells are transduced with a lentiviral vector carrying a functional WAS cDNA.
• Phase I/II trials (e.g., NIH) show promising immune reconstitution and platelet recovery, but long‑term safety data are still being collected.

Supportive care

• Immunoglobulin replacement therapy (IVIG or subcutaneous IG): Maintains IgG trough levels > 500 mg/dL, reduces bacterial infections.
• Antimicrobial prophylaxis:
  • Trimethoprim‑sulfamethoxazole (TMP‑SMX) for PCP prophylaxis.
  • Azithromycin or clarithromycin for recurrent pneumococcal infections.
• Platelet transfusions: Reserved for severe bleeding or prior to surgery.
• Topical and systemic management of eczema: Emollients, low‑potency topical corticosteroids, and, if needed, calcineurin inhibitors.
• Autoimmune disease treatment: Short courses of corticosteroids, mycophenolate, or rituximab; HSCT often resolves autoimmunity.

Vaccination strategy

• Live vaccines (e.g., MMR, varicella) are contraindicated unless immune reconstitution is confirmed post‑HSCT.
• Inactivated vaccines (influenza, pneumococcal conjugate) are recommended and should be given annually or per schedule.

Lifestyle and preventive measures

• Good hand hygiene and avoidance of sick contacts.
• Prompt treatment of skin breaks to prevent secondary infection.
• Dental care to reduce oral bacterial load.

Living with X‑linked Primary Immunodeficiency (Wiskott‑Aldrich Syndrome)

While medical treatment is critical, day‑to‑day management empowers patients and families to maintain a quality life.

Home care tips

• Bleeding precautions: Use soft toothbrushes, avoid NSAIDs/aspirin, and wear protective gear during sports.
• Infection vigilance: Keep a log of fevers, cough, or skin lesions and seek medical evaluation promptly.
• Skin care regimen: Apply fragrance‑free moisturizers multiple times daily; limit hot showers that can dry skin.
• Medication adherence: Set alarms or use pill organizers for IVIG, prophylactic antibiotics, and immunosuppressants.

School and social considerations

• Develop an Individualized Health Plan (IHP) with school nurses outlining bleeding precautions and infection‑control measures.
• Educate teachers and classmates about the need to avoid sharing personal items (e.g., lip balm, toothbrushes).
• Encourage participation in low‑impact activities (swimming with a swim cap, walking clubs) while avoiding high‑risk contact sports.

Psychosocial support

• Connect with patient advocacy groups such as the Wiskott‑Aldrich Foundation for peer support.
• Consider counseling to address anxiety related to chronic illness and potential isolation.
• Plan for transition to adult care—identify a primary immunologist and hematologist experienced in post‑HSCT follow‑up.

Prevention

Because WAS is genetic, true primary prevention is limited, but several strategies reduce disease impact:

• Carrier testing: Offer genetic counseling and testing to female relatives of an affected boy.
• Prenatal diagnosis: Chorionic villus sampling or amniocentesis with targeted WAS mutation analysis for at‑risk pregnancies.
• Pre‑implantation genetic testing (PGT‑M): For couples undergoing IVF, embryos without the pathogenic variant can be selected.
• Early newborn screening: While not standard worldwide, some centers incorporate platelet count assessments to flag severe thrombocytopenia prompting further work‑up.

Complications

If left untreated or inadequately managed, WAS can lead to serious, life‑threatening problems:

• Severe hemorrhage: Intracranial or gastrointestinal bleeding.
• Chronic lung disease: Bronchiectasis from recurrent pneumonias.
• Autoimmune disease: AIHA, ITP, or vasculitis requiring long‑term immunosuppression.
• Malignancy: Lymphoma or AML, with a cumulative risk of 13–20 % by age 30 (Cleveland Clinic, 2022).
• Growth failure and developmental delay: Secondary to chronic illness and repeated hospitalizations.
• Transplant‑related complications: Graft‑versus‑host disease, opportunistic infections, or organ toxicity.

When to Seek Emergency Care

---

References: Mayo Clinic. “Wiskott‑Aldrich syndrome.” 2023; CDC. Primary Immunodeficiency Fact Sheet, 2022; NIH Genetic and Rare Diseases Information Center, 2024; Cleveland Clinic. “Wiskott‑Aldrich syndrome overview.” 2022; WHO. Guidelines for the Management of Primary Immunodeficiency Disorders, 2021.

```